A detailed history of Salomon & Ludwin, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Salomon & Ludwin, LLC holds 2 shares of BGNE stock, worth $384. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2
Previous 2 -0.0%
Holding current value
$384
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 02, 2024

BUY
$141.8 - $181.47 $283 - $362
2 New
2 $0

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $19.9B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Salomon & Ludwin, LLC Portfolio

Follow Salomon & Ludwin, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Salomon & Ludwin, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Salomon & Ludwin, LLC with notifications on news.